SANOFI80 Stock Overview
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Sanofi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.62 |
| 52 Week High | €3.70 |
| 52 Week Low | €3.58 |
| Beta | 0.42 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -0.55% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| SANOFI80 | TH Pharmaceuticals | TH Market | |
|---|---|---|---|
| 7D | -1.6% | -1.5% | -1.8% |
| 1Y | n/a | 15.4% | 5.1% |
Return vs Industry: Insufficient data to determine how SANOFI80 performed against the TH Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how SANOFI80 performed against the TH Market.
Price Volatility
| SANOFI80 volatility | |
|---|---|
| SANOFI80 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in TH Market | 11.1% |
| 10% least volatile stocks in TH Market | 2.5% |
Stable Share Price: SANOFI80's share price has been volatile over the past 3 months compared to the TH market.
Volatility Over Time: Insufficient data to determine SANOFI80's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 86,088 | Paul Hudson | www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Sanofi Fundamentals Summary
| SANOFI80 fundamental statistics | |
|---|---|
| Market cap | ฿4.56t |
| Earnings (TTM) | ฿163.76b |
| Revenue (TTM) | ฿1.76t |
27.8x
P/E Ratio2.6x
P/S RatioIs SANOFI80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANOFI80 income statement (TTM) | |
|---|---|
| Revenue | €48.45b |
| Cost of Revenue | €14.96b |
| Gross Profit | €33.48b |
| Other Expenses | €28.98b |
| Earnings | €4.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 3.59 |
| Gross Margin | 69.12% |
| Net Profit Margin | 9.30% |
| Debt/Equity Ratio | 32.5% |
How did SANOFI80 perform over the long term?
See historical performance and comparison